GLPwatch
WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults
NCT07216651 · Completed
Last updated 2026-05-28This study is testing how long adults in the U.S. with obesity or overweight stay on personalized doses of semaglutide, a medication used for weight management.
Status Completed The study has finished.
Type Observational
Participants 20 people
Who can join Ages 18+ · all sexes
Timeline Started 2025-09 · est. completion 2026-03
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT07216651 ↗
Description as written by the study sponsor.
This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucagon-like peptide-1 (GLP-1) drug treatment such as semaglutide.
| Main thing measured | Percentage of participants who persisted on semaglutide treatment over the study period |
|---|---|
| Sponsor | Closed Loop Medicine |
| Conditions studied | Obesity & Overweight |
| GLP-1 drugs | semaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07216651 ↗